Use of Anticancer Therapies and Economic Burden Near the End of Life in Japan: Results From Claims Database.

Yusuke Kajimoto Kazunori Honda Kazuki NozawaMineko MukaiLida TengAtaru Igarashi

Published in: JCO global oncology (2022)

We found the percentage of patients receiving anticancer therapies within 14 days of death in Japan, its associated factors, and economic burden. Our findings can serve as a benchmark for optimizing EOL care.

Keyphrases

healthcare
palliative care
health insurance
quality improvement
affordable care act
adverse drug